플러스100%마이너스

  • 화면크기
통합검색

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial.

Authors

Asher GN, Viera AJ, Weaver MA, Dominik R, Caughey M, Hinderliter AL.

Journal

BMC Complement Altern Med.

Year

2012

Vol (Issue)

12

Page

26.

doi

10.1186/1472-6882-12-26.

PMID

22458601

Url

http://www.ncbi.nlm.nih.gov/pubmed/22458601

MeSH

Adult
Aged
Biflavonoids/pharmacology*
Biflavonoids/standards
Blood Circulation/drug effects
Blood Pressure/drug effects
Brachial Artery/drug effects
Catechin/pharmacology*
Catechin/standards
Crataegus/chemistry*
Cross-Over Studies
Humans
Hypertension/blood*
Hypertension/drug therapy
Middle Aged
Nitric Oxide/blood*
Patient Acceptance of Health Care
Phytotherapy
Plant Extracts/pharmacology*
Proanthocyanidins/pharmacology*
Proanthocyanidins/standards
Vasodilation/drug effects*

Keywords

Hawthorn; Crataegus; hypertension; prehypertension; flow mediated dilation; Phase I

한글 키워드

산사나무; 산사; 고혈압; 고혈압 전 단계; 흐름 매개 확장; 임상시험 1상

KMCRIC summary and commentary

없음

Korean Study

Abstract

BACKGROUND: Hawthorn extract has been used for cardiovascular diseases for centuries. Recent trials have demonstrated its efficacy for the treatment of heart failure, and the results of several small trials suggest it may lower blood pressure. However, there is little published evidence to guide its dosing. The blood pressure lowering effect of hawthorn has been linked to nitric oxide-mediated vasodilation. The aim of this study was to investigate the relationship between hawthorn extract dose and brachial artery flow mediated dilation (FMD), an indirect measure of nitric oxide release.
METHODS: We used a four-period cross-over design to evaluate brachial artery FMD in response to placebo or hawthorn extract (standardized to 50 mg oligomeric procyanidin per 250 mg extract). Randomly sequenced doses of hawthorn extract (1000 mg, 1500 mg, and 2500 mg) and placebo were assigned to each participant. Doses were taken twice daily for 3 1/2 days followed by FMD and a 4-day washout before proceeding to the next dosing period.
RESULTS: Twenty-one prehypertensive or mildly hypertensive adults completed the study. There was no evidence of a dose-response effect for our main outcome (FMD percent) or any of our secondary outcomes (absolute change in brachial artery diameter and blood pressure). Most participants indicated that if given evidence that hawthorn could lower their blood pressure, they would be likely to use it either in conjunction with or instead of lifestyle modification or anti-hypertensive medications.
CONCLUSION: We found no evidence of a dose-response effect of hawthorn extract on FMD. If hawthorn has a blood pressure lowering effect, it is likely to be mediated via an NO-independent mechanism.
TRIAL REGISTRATION: This trial has been registered with ClinicalTrials.gov, a service of the U.S. National Institutes of Health: NCT01331486.

국문초록

Language

영어

첨부파일